—
C+
C+ The full Closelooknet — membership. Open the C+ overview

APGE.US (APGE) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for APGE, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.40 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How APGE has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.40 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), APGE.US moved 0.40% on average · correlation 0.05 · higher than 40% of US names
  • Beta, last 3 months −1.31 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.47% on average against −0.74% for the S&P 500 the 7 sessions of the past year in which TLT fell most, i.e. long yields rose most

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against APGE on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — APGE.US

APGE in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, building a pipeline of monoclonal antibodies for conditions such as atopic dermatitis, asthma and chronic obstructive pulmonary disease. Its lead candidates target pathways including OX40L, IL-4Ra and TSLP, and are designed to let patients inject less often. Founded in 2022 and based in San Francisco, the company now operates as a subsidiary of AbbVie.
Where it sits in the stack
Apogee holds no seat in our index; it sits in the Healthcare sector of the Closelooknet universe, among US drug developers the diary follows for pipeline progress and balance-sheet risk rather than for any place in the AI build-out.
Who it is priced against
Closelooknet's peer group compares it with other scored Healthcare names based in the US, including argenx, Regeneron and Vertex, grouped for sharing sector and country rather than mechanism; the market also names Amgen as a comparable immunology developer.
Why Closelooknet tracks it
Apogee carries a Closelooknet score built from two of the module set so far, with momentum reading stronger than quality; it holds no seat in our index and the diary has not yet quoted it in an edition.
What the diary watches
The diary watches how Apogee's pipeline programmes are reported now that it operates as an AbbVie subsidiary, since that change in ownership affects how trial results and disclosures reach the market.

APGE.US (APGE) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Truist, 2026-08-13

The Street on this name

Analyst actions and the latest print for APGE from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 135 from 81 Target raised to $135 from $81 (+0.3% to spot) 2026-08-13

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is APGE.US (APGE)?

APGE.US trades as APGE on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is APGE in a Closelooknet index?

Not currently — APGE.US is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does APGE trade against its moving averages?

Uptrend stack intact: Trades +0.7% vs the 50-day and +46.3% vs the 200-day average, 0% below the 52-week high and +281.7% off the 52-week low. Computed from daily closes. As of 2026-09-03 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does APGE.US compare with its peers?

Against its peer group (Biotechnology · US), APGE.US (APGE) sits at its 52-week high, 0.7% above its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to APGE in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does APGE.US trade when bond yields rise?

Over the past year APGE.US had a beta of 0.40 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 40% of US names. On the 7 sessions in which long bonds fell most it moved −1.47% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does APGE.US do?

Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, building a pipeline of monoclonal antibodies for conditions such as atopic dermatitis, asthma and chronic obstructive pulmonary disease. Its lead candidates target pathways including OX40L, IL-4Ra and TSLP, and are designed to let patients inject less often. Founded in 2022 and based in San Francisco, the company now operates as a subsidiary of AbbVie. Closelooknet's peer group compares it with other scored Healthcare names based in the US, including argenx, Regeneron and Vertex, grouped for sharing sector and country rather than mechanism; the market also names Amgen as a comparable immunology developer.

Where does APGE.US sit in the AI build-out?

Apogee holds no seat in our index; it sits in the Healthcare sector of the Closelooknet universe, among US drug developers the diary follows for pipeline progress and balance-sheet risk rather than for any place in the AI build-out. Apogee carries a Closelooknet score built from two of the module set so far, with momentum reading stronger than quality; it holds no seat in our index and the diary has not yet quoted it in an edition.

What has Wall Street done on APGE.US recently?

The most recent analyst action on APGE.US on the Closelooknet wire is a price target by Truist on 2026-08-13 (target 135 from 81). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for APGE, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.